Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial-Reference-Cited by-同舟云学术

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

Published:2017-07 Issue:7 Volume:18 Page:929-945
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cameron David,Morden James P,Canney Peter,Velikova Galina,Coleman Robert,Bartlett John,Agrawal Rajiv,Banerji Jane,Bertelli Gianfilippo,Bloomfield David,Brunt A Murray,Earl Helena,Ellis Paul,Gaunt Claire,Gillman Alexa,Hearfield Nicholas,Laing Robert,Murray Nicholas,Couper Niki,Stein Robert C,Verrill Mark,Wardley Andrew,Barrett-Lee Peter,Bliss Judith M

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials;Peto;Lancet,2012

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

3. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

4. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial;Ellis;Lancet,2009

5. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer;Martin;J Natl Cancer Inst,2008

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial;Journal of Clinical Oncology;2024-09-10

2. Use of routinely collected health data (England) to identify subsequent disease-related events in patients with primary breast cancer: A practical alternative to hospital-based follow-up for breast cancer clinical trials;2024-09-08

3. Controversies on chemotherapy for early HR+/HER2− breast cancer: the role of anthracyclines and dose intensification;Current Opinion in Oncology;2024-06-13

4. Fusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteria;Chem;2024-06

5. Change of dosing paradigm in oncology;Forum of Clinical Oncology;2024-05-20